Cathepsins and pancreatic cancer: The 2012 update

Pancreatology

Volumn 12, Issue 5, 2012, Pages 395-401

  Sulpizio, Sara ^a   Franceschini, Nicola ^a   Piattelli, Adriano ^b   Di Sebastiano, Pierluigi ^c   Innocenti, Paolo ^b   Selvaggi, Federico ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Cathepsin; Cathepsin inhibitor; Pancreatic cancer; Protease

Indexed keywords

3 TRANS(PROPYLCARBAMOYL)OXIRANE 2 CARBONYL ISOLEUCYL PROLINE METHYL ESTER; CA 074ME; CATHEPSIN; CATHEPSIN B; CATHEPSIN B INHIBITOR; CATHEPSIN D; CATHEPSIN E; CATHEPSIN H; CATHEPSIN L; CATHEPSIN S; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; CANCER GROWTH; CARCINOGENESIS; CHRONIC PANCREATITIS; GENE MUTATION; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; INSULINOMA; INTRACELLULAR SIGNALING; LOCAL METASTASIS; LYSOSOME; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SECRETORY GRANULE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84873084257     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1016/j.pan.2012.07.011     Document Type: Review

References (70)

1. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010 Apr 20; 7(4): e1000267.
2. Neoptolemos JP, Dunn JA, Stocken D.D., Almond J., Link K, Beger H, et a.l., European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001 Nov 10; 358(9293): 1576-85. (Pubitemid 33101907)
3. Zou YP, Li WM, Zheng F, Li F.C., Huang H., Du JD, et al Intraoperative radio-frequency ablation combined with 125 iodine seed implantation for unre-sectable pancreatic cancer. World J Gastroenterol 2010 Oct 28; 16(40): 5104-10.
4. Reni M, Cereda S, Balzano G., Passoni P, Rognone A, Zerbi A., et al Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2009 Nov; 64(6): 1253-9.
5. Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A., Tambaro R, et al A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010 Jan; 17(1): 194-205.
6. Edling C, Selvaggi F, Buus R., Maffucci T, di Sebastiano P, Friess H, et al Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 2010 Oct 15; 16(20): 4928-37.
7. Falasca M, Selvaggi F, Buus R., Sulpizio S, Edling C. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials. Anticancer Agents Med Chem 2011 Jun; 11(5): 456-63.
8. Mohamed MM, Sloane BF Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006 Oct; 6(10): 764-75. Review. (Pubitemid 44450465)
9. Gopinathan A, Denicola GM, Frese K.K., Cook N., Karreth FA, Mayerle J, et al Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut 2011 Dec 9. Epub ahead of print.
10. Eser S, Messer M, Eser P., Von Werder A, Seidler B, Bajbouj M., et al In vivo diagnosis of murine pancreatic intraepithelial neoplasia and early-stage pancreatic cancer by molecular imaging. PNAS 2011 June; 108(14): 9945-50.
11. Cruz-Monserrate Z., Abd-Elgaliel WR, Grote T., Deng D, Ji B, Arumugam T., et al Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models. Gut 2011 Nov 22. Epub ahead of print.
12. Michl P. Targeting cathepsins: a new glimmer of hope for pancreatic cancer therapy? Gut 2012 Jun; 61(6): 790-1. Epub 2012 Jan 27.
13. Joyce JA, Baruch A, Chehade K., Meyer-Morse N, Giraudo E, Tsai F.Y., et al Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004 May; 5(5): 443-53. (Pubitemid 38610246)
14. Chwieralski CE, Welte T, Bühling F. Cathepsin-regulated apoptosis. Apoptosis 2006 Feb; 11(2): 143-9. Review. (Pubitemid 43291015)
15. Palermo C, Joyce JA Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008 Jan; 29(1): 22-8. Epub 2007 Nov 26.
16. Gocheva V, Zeng W, Ke D., Klimstra D, Reinheckel T, Peters C., et al Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006 Mar 1; 20(5): 543-56. Epub 2006 Feb 15. (Pubitemid 43345321)
17. Sloane BF, Sameni M, Podgorski I., Cavallo-Medved D, Moin K. Functional imaging of tumor proteolysis. Annu Rev Pharmacol Toxicol 2006; 46: 301-15. Review. (Pubitemid 43271192)
18. Lankelma JM, Voorend DM, Barwari T, Koetsveld J., Van der Spek AH, De Porto AP, et al. Cathepsin L, target in cancer treatment? Life Sci 2010 Feb 13; 86(7-8): 225-33. Epub 2009 Nov 30. Review.
19. Felbor U, Dreier L, Bryant R.A., Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. Microbiol Mol Biol Rev 1998 Sep; 62(3): 597-635. Review.
20. Meister T, Niehues R, Hahn D., Domschke W, Sendler M, Lerch M.M., et al Missorting of cathepsin B into the secretory compartment of CI-MPR/ IGFIIdeficient mice does not induce spontaneous trypsinogen activation but leads to enhanced trypsin activity during experimental pancreatitisewithout affecting disease severity. J Physiol Pharmacol 2010 Oct; 61(5): 565-75.
21. Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G., Carta G, Franceschini N, et al Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles. Neoplasia 2008 May; 10(5): 481-8. (Pubitemid 351657390)
22. Turk V, Kos J, Turk B. Cysteine cathepsins (proteases)eon the main stage of cancer? Cancer Cell. 2004 May; 5(5): 409-10. (Pubitemid 38610242)
23. Dudeja V, Mujumdar N, Phillips P., Chugh R, Borja-Cacho D, Dawra RK, et al Heat shock protein 70 inhibits apoptosis in cancer cells through simultaneous and independent mechanisms. Gastroenterology 2009 May; 136(5): 1772-82. Epub 2009 Feb 6.
24. Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 2003 Jun-Sep; 22(2-3): 271-86. Review. (Pubitemid 36561062)
25. Rao MB, Tanksale AM, Ghatge M.S., Deshpande VV Molecular and biotechnological aspects of microbial proteases. Microbiol Mol Biol Rev 1998 Sep; 62(3): 597-635. Review. (Pubitemid 28415546)
26. Rozhin J, Sameni M, Ziegler G., Sloane BF Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 1994 Dec 15; 54(24): 6517-25.
27. Gocheva V, Chen X, Peters C., Reinheckel T, Joyce JA Deletion of cathepsin H perturbs angiogenicswitching, vascularizationandgrowthoftumorsinamouse model of pancreatic islet cell cancer. Biol Chem 2010 Aug; 391(8): 937-45.
28. Ohta T, Terada T, Nagakawa T., Tajima H, Itoh H, Fonseca L., et al Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions. Br J Cancer 1994 Jan; 69(1): 152-6. (Pubitemid 24021839)
29. Van Acker G.J., Saluja AK, Bhagat L, Singh V.P., Song AM, Steer ML Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. Am J Physiol Gastrointest Liver Physiol 2002 Sep; 283(3): G794-800. (Pubitemid 34920370)
30. Niedergethmann M, Wostbrock B, Sturm J.W., Willeke F., Post S, Hildenbrand R. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004 Oct; 29(3): 204-11. (Pubitemid 39304977)
31. Niedergethmann M, Hildenbrand R, Wolf G., Werbeke CS, Richter A, Post S. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000 Aug; 28(1): 31-9.
32. Nagai A, Murakawa Y, Terashima M., Shimode K, Umegae N, Takeuchi H., et al Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology 2000 Dec 26; 55(12): 1828-32. (Pubitemid 32103964)
33. Yanamandra N, Gumidyala KV, Waldron K.G., Gujrati M., Olivero WC, Dinh DH, et al Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene 2004 Mar 18; 23(12): 2224-30. (Pubitemid 38482537)
34. Krueger S, Haeckel C, Buehling F., Roessner A. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res 1999 Dec 1; 59(23): 6010-4. (Pubitemid 30004966)
35. Podgorski I, Linebaugh BE, Sameni M, Jedeszko C., Bhagat S, Cher ML, et al Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 2005 Mar; 7(3): 207-23. (Pubitemid 40411633)
36. Ulbricht B, Henny H, Horstmann H., Spring H, Faigle W, Spiess E. Influence of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) on the localization of cathepsin B and cathepsin L in human lung tumor cells. Eur J Cell Biol 1997 Nov; 74(3): 294-301. (Pubitemid 27490221)
37. Szpaderska AM, Silberman S, Ahmed Y., Frankfater A. Sp1 regulates cathepsin B transcription and invasiveness in murine B16 melanoma cells. Anticancer Res 2004 Nov-Dec;24(6): 3887-91. (Pubitemid 40468681)
38. Reddy VY, Zhang QY, Weiss SJ Pericellular mobilization of the tissuedestructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. Proc Natl Acad Sci U S A 1995 Apr 25; 92(9): 3849-53.
39. Leto G, Tumminello FM, Pizzolanti G, Montalto G., Soresi M, Carroccio A, et al Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas 1997 Jan; 14(1): 22-7. (Pubitemid 26427254)
40. Joergensen MT, Geisz A, Brusgaard K., Schaffalitzky de Muckadell OB, Hegyi P, Gerdes AM, et al. Intragenic duplication: a novel mutational mechanism in hereditary pancreatitis. Pancreas 2011 May; 40(4): 540-6.
41. Weiss FU, Behn CO, Simon P, Ruthenbürger M, Halangk W., Lerch MM Cathepsin B gene polymorphism Val26 is not associated with idiopathic chronic pancreatitis in European patients. Gut 2007 Sep; 56(9): 1322-3. No abstract available. (Pubitemid 47300439)
42. Mahurkar S, Idris MM, Reddy D.N., Bhaskar S., Rao GV, Thomas V, et al Association of cathepsin B gene polymorphisms with tropical calcific pancreatitis. Gut 2006 Sep; 55(9): 1270-5. Epub 2006 Feb 21. (Pubitemid 44304037)
43. Conlon JM, Höög A, Grimelius L. Intracellular degradation of the C-peptide of proinsulin, in human insulinoma: identification of sides of cleavage and evidence for the role of cathepsin B. Pancreas 1995 Mar; 10(2): 167-72.
44. Im B, Kominami E, Grube D., Uchiyama Y. Immunocytochemical localization of cathepsins B and H in human pancreatic endocrine cells and insulinoma cells. Histochemistry 1989; 93(2): 111-8. (Pubitemid 20001176)
45. Zhang C, Sun JB, Liu D.C., Cui YQ, Liu S, Sun HC Preliminary research on the pathological role of cathepsin-B in subcutaneous heteroplastic pancreatic carcinoma in nude mice. Chin Med J (Engl) 2009 Oct 20; 122(20): 2489-96.
46. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005 Feb; 52(1-2): 1-9. Review.
47. Guicciardi ME, Leist M, Gores GJ Lysosomes in cell death. Oncogene 2004; 23: 2881-90. (Pubitemid 38638850)
48. Chen R, Brentnall TA, Pan S, Cooke K., Moyes KW, Lane Z, et al Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007; 6: 1331-42. (Pubitemid 47365432)
49. Shen J, Person MD, Zhu J, Abbruzzese J.L., Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 2004 Dec 15; 64(24): 9018-26. (Pubitemid 39665512)
50. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M., Missiaglia E, Ruszniewski P, et al Characterization of gene expression profiles in intraductal papillarymucinous tumors of the pancreas. Am J Pathol 2002; 160(5): 1745-54. (Pubitemid 34525654)
51. Azuma T, Hirai M, Ito S., Yamamoto K, Taggart RT, Matsuba T, et al Expression of cathepsin E in pancreas: a possible tumor marker for pancreas, a preliminary report. Int J Cancer 1996 Aug 7; 67(4): 492-7. (Pubitemid 26274104)
52. Uno K, Azuma T, Nakajima M., Yasuda K, Hayakumo T, Mukai H., et al Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. Gastroenterol Hepatol 2000 Nov; 15(11): 1333-8.
53. Fukushima N, Sato N, Prasad N., Leach SD, Hruban RH, Goggins M. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 2004; 23: 9042-51. (Pubitemid 40013071)
54. Paciucci R, Berrozpe G, Torà M, Navarro E, Garcia de Herreros A, Real FX. Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using substrate hybridization. FEBS Lett 1996 Apr 29; 385(1-2): 72-6. (Pubitemid 26155086)
55. del Re E.C., Shuja S, Cai J., Murnane MJ Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas. Br J Cancer 2000 Apr; 82(7): 1317-26. (Pubitemid 30145352)
56. Waghray A, Keppler D, Sloane B.F., Schuger L., Chen YQ Analysis of a truncated form of cathepsin H in human prostate tumor cells. Biol Chem 2002 Mar 29; 277(13): 11533-8. Epub 2002 Jan 16. (Pubitemid 34952924)
57. Wartmann T, Mayerle J, Kähne T, Sahin-Tóth M, Ruthenbürger M, Matthias R, et al. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology 2010 Feb; 138(2): 726-37. Epub 2009 Nov 10.
58. Goulet B, Sansregret L, Leduy L., Bogyo M, Weber E, Chauhan S.S., et al Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol Cancer Res 2007 Sep; 5(9): 899-907. (Pubitemid 47416667)
59. Wang B, Sun J, Kitamoto S., Yang M, Grubb A, Chapman H.A., et al Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006 Mar 3; 281(9): 6020-9. Epub 2005 Dec 19. (Pubitemid 43847703)
60. Kwok HF, Buick RJ, Kuehn D, Gormley J.A., Doherty D., Jaquin TJ, et al Antibody targeting of cathepsin S induces antibody-dependent cellular cytotoxicity. Mol Cancer 2011 Dec; 10(14): 147.
61. Bell-McGuinn K.M., Garfall AL, Bogyo M, Hanahan D., Joyce JA Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 2007 Aug; 67(15): 7378-85. (Pubitemid 47206568)
62. Van Noorden CJF, Jonges TGN, Meade-Tollin LC, Smith RE, Koehler A. In vivo inhibition of cysteine proteinases delays the onset of growth of human pancreatic cancer explants. Br J Cancer 2000 Feb; 82(4): 931-6. (Pubitemid 30085248)
63. Hosokawa M, Kashiwaya K, Eguchi H., Ohigashi H, Ishikawa O, Furihata M., et al Over-expression of cysteine proteinase inhibitor cystatin 6 promotes pancreatic cancer growth. Cancer Sci 2008 Aug; 99(8): 1626-32.
64. Watanabe M, Watanabe T, Ishii Y., Matsuba H, Kimura S, Fujita T., et al Immunocytochemical localization of cathepsins B, H and their endogenous inhibitor, cystatin beta, in islet endocrine cells of rat pancreas. J Histochem Cytochem 1988 Jun; 36(7): 783-91.
65. Elie BT, Gocheva V, Shree T., Dalrymple SA, Holsinger LJ, Joyce JA Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie 2010 Nov; 92(11): 1618-24. Epub 2010 May 4.
66. Costa AG, Cusano NE, Silva B.C., Cremers S., Bilezikian JP Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011 Jun 14; 7(8): 447-56.
67. Brömme D., Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009 May; 18(5): 585-600.
68. Yan X, Takahara M, Xie L., Oda Y, Nakahara T, Uchi H., et al Stromal expression of cathepsin K in squamous cell carcinoma. J Eur Acad Dermatol Venereol 2011 Mar; 25(3): 362-5.
69. Jensen AB, Wynne C, Ramirez G., He W, Song Y, Berd Y., et al The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010 Dec 1; 10(6): 452-8.
70. Quintanilla-Dieck M.J., Codriansky K, Keady M., Bhawan J, Rünger TM. Cathepsin K in melanoma invasion. J Invest Dermatol 2008 Sep; 128(9): 2281-8. Epub 2008 Mar 27.